Cargando…
KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers
BACKGROUND: Mitochondrial disorders are a clinically, biochemically and genetically heterogeneous group of multi-system diseases, with an unmet medical need for treatment. KH176 is an orally bio-available small molecule under development for the treatment of mitochondrial(−related) diseases. The com...
Autores principales: | Koene, Saskia, Spaans, Edwin, Van Bortel, Luc, Van Lancker, Griet, Delafontaine, Brant, Badilini, Fabio, Beyrath, Julien, Smeitink, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644106/ https://www.ncbi.nlm.nih.gov/pubmed/29037240 http://dx.doi.org/10.1186/s13023-017-0715-0 |
Ejemplares similares
-
The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders
por: Janssen, Mirian C.H., et al.
Publicado: (2018) -
Sonlicromanol’s active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth
por: Jiang, Xiaolan, et al.
Publicado: (2021) -
Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease
por: de Haas, Ria, et al.
Publicado: (2017) -
KH176 Safeguards Mitochondrial Diseased Cells from Redox Stress-Induced Cell Death by Interacting with the Thioredoxin System/Peroxiredoxin Enzyme Machinery
por: Beyrath, Julien, et al.
Publicado: (2018) -
Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE(2) biosynthesis by sonlicromanol’s metabolite KH176m
por: Jiang, X., et al.
Publicado: (2021)